Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Novartis India Ltd (NOVARTIND) is currently trading at 916.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Novartis India Limited (NIL) is a subsidiary of the Swiss pharmaceutical company Novartis. It primarily operates in manufacturing and marketing drugs across pharmaceuticals, generics, over-the-counter, and animal health products. Novartis' history is marked by major mergers, starting with the merge of Ciba and Geigy in 1970, leading to the formation of Novartis in 1996 after Sandoz joined. This historical consolidation forms the backbone of their capabilities today. The company has a strong CSR presence, having partnered with WHO on several health initiatives including malaria and tuberculosis efforts, which underscores their commitment to global health issues. NIL has initiated several marketing strategies, including the 'Arogya Parivar' program targeting healthcare needs in rural India, highlighting their approach to differentiated healthcare solutions. The company has engaged in strategic partnerships for distribution, notably with Nutri-Ad International for poultry feed supplements and Johnson & Johnson Limited for veterinary sutures, enhancing their product reach.
Over the past 52 weeks, Novartis India Ltd has traded between a low of ₹744.95 and a high of ₹1,099.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Novartis India Ltd has a market capitalization of approximately 2,272.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Novartis India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.37 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,272.91 Cr, Novartis India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Novartis India Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Novartis India Ltd is 23.37. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The sale is part of Novartis AG's global strategy to transform into a pure-play innovative medicines company and follows a strategic review of its assets.
Novartis AG is selling its stake as part of a global strategy to transform into a 'pure-play innovative medicines company,' focusing on patented therapies and streamlining its worldwide operations.
Novartis AG is selling its 70.68% stake as part of a global strategic review to transform into a 'pure-play innovative medicines company' and focus on its core R&D and new drug portfolio.
Novartis AG is selling its stake as part of a global strategic review to transform into a 'pure-play innovative medicines company' and streamline its worldwide operations.
Detailed Public Statement
Axis Capital filed a Detailed Public Statement for an open offer by WaveRise, ChrysCapital Fund X and Two Infinity Partners (with PACs) to acquire up to 6,419,608 equity shares (26% of voting capital) of Novartis India; underlying SPA contemplates acquisition of 17,450,680 shares (70.68%) from Novartis AG.
Open Offer
Axis Capital (Manager) published a Detailed Public Statement that WaveRise, ChrysCapital Fund X and Two Infinity Partners (with PACs) will make an open offer to acquire up to 64,19,608 equity shares (26% of voting capital) of Novartis India; this follows an SPA under which 1,74,50,680 shares (70.68%) are being acquired from Novartis AG.
Open Offer
Novartis India received a Detailed Public Statement dated 26-Feb-2026 for an open offer by WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners (with PACs) to acquire up to 6,419,608 shares (26% of voting capital); Axis Capital is manager.
Open Offer DPS
Novartis India received a Detailed Public Statement dated 26‑Feb‑2026: WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners (with PACs) propose an open offer to acquire 6,419,608 shares (26% of voting capital) under SEBI SAST.
Bearish
3
Neutral
7
Bullish
4
Bearish
11
Neutral
7
Bullish
28
Bearish
8
Neutral
0
Bullish
24
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
272.50 | 2,718 Cr | 54.61 | 4.31 | 0.04 | 9.02 | 10.81 | 3.94 | |
164.50 | 2,574 Cr | 21.73 | 0.40 | 0.00 | 2.14 | 3.12 | 1.07 | |
920.55 | 2,273 Cr | 23.37 | 2.93 | 2.71 | 13.75 | 17.93 | 10.43 | |
320.00 | 2,264 Cr | 7.66 | 0.93 | 0.00 | 5.98 | 6.30 | 8.29 | |
40.75 | 2,233 Cr | 22.64 | 1.87 | 0.49 | 6.31 | 8.14 | 5.77 | |
70.55 | 2,059 Cr | 17.86 | 1.18 | 1.14 | 6.62 | 9.15 | 4.80 | |
458.55 | 2,016 Cr | -95.38 | 1.34 | 0.00 | 0.51 | 5.47 | -0.83 |
Novartis India Limited (NIL) is a subsidiary of the Swiss pharmaceutical company Novartis. It primarily operates in manufacturing and marketing drugs across pharmaceuticals, generics, over-the-counter, and animal health products.
Novartis' history is marked by major mergers, starting with the merge of Ciba and Geigy in 1970, leading to the formation of Novartis in 1996 after Sandoz joined. This historical consolidation forms the backbone of their capabilities today.
The company has a strong CSR presence, having partnered with WHO on several health initiatives including malaria and tuberculosis efforts, which underscores their commitment to global health issues.
NIL has initiated several marketing strategies, including the 'Arogya Parivar' program targeting healthcare needs in rural India, highlighting their approach to differentiated healthcare solutions.
The company has engaged in strategic partnerships for distribution, notably with Nutri-Ad International for poultry feed supplements and Johnson & Johnson Limited for veterinary sutures, enhancing their product reach.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
2,273 Cr
Low Risk
23.4
27.5
1.3
2.9
1,099.90
744.95
Sales CAGR
Profit CAGR
ROE
ROCE
